Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
excellent, Nolerman. definitely a bigger problem than politics.
one good consequence of the sequester is the debt is reducing at a greater rate.
I'm so sorry to hear about Susan. She was a brilliant and most of all courageous trader. She was a big part of this fine group of people, that I always have looked up to in my time on the hub. I think sbt will be looking down on you.
Lindy
great board! i'm doing the same.
Z, Michelle Caruso Cabrera on cnbc was talking about means testing of medicare for billionaires and the super rich who don't need it. It sounds practical. There are so many bipartisan ways to cut the fat and pork. I don't get why these people can't reach agreements
test
test
test
super, Neil Young fans:) me too.
A Case For Bank Of America
September 14, 2012 | 22 commentsby: Golden Hammer | about: BAC Disclosure: I am long BAC. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)
Equities surged to their highest point in years today with the news of QE3 hitting the markets. Financials were rewarded the most this week with the anticipation of this news, some yielding 10%+ returns. Bank of America (BAC) was among those included with a staggering +17.65% since last Friday. These recent upheavals have now left the average financial investor with their finger on the trigger wondering if it's time to take the money and run. I would argue against this action for the following three reasons.
First, this new form of QE3 aims to take measures to significantly reduce the unemployment rate by pumping monthly expenditure into mortgage debt relief until it sees a significant improvement. This guarantees the financial sector is lower borrowing rates and additional relief for their mortgage exposure. With this new blessing from the Fed, they can now start focusing on lending again instead of strict reserve requirements. These actions will significantly add to the profitability of Bank of America as well as the rest of the financial sector.
Secondly, I would argue that the majority of these financials remain extremely attractive as they continue to trade far below their tangible book values. My favorite case for this argument is Bank of America . Until this past week it had been trading at a level that was below 50% of its price to book ratio. During the past year, the company has continued to demonstrate strong positive growth in its balance sheet, a focused restructuring of its core assets, a boost in cash flow due to its sale of non-core assets, and a significant increase in consumer confidence apparent in its 69.06% gain since 01/01/2012. Let us not forget about a possibility of an increase in its dividend sometime in the near future.
Lastly, the company has seen a significant reduction in its liabilities on the balance sheet. The past 5 years have left the Bank of America with an questionable future as far as its toxic debt exposure, constant lawsuits, and strict fiscal policy requirements which have impeded the profitability of the company as well as the return for its shareholders. In my opinion, this cloud of hesitation is now being dissipated as the majority of lawsuits have been settled, losses have been account for, and with this new form of QE3, their cash flow will continue to flow. With this pattern of growth, I see nothing but success for Bank of America over the next year and returns that could push this stock back up towards its 4 year highs.
I second that! I'm guilty of not posting much, but follow sss all i can and thank you for all you do. I also want to add Feddie today, great posts made me $$$. Then look at Zephyr's posts last week filled with wisdom, guidance and even warnings in real-time, always 'on top of' the market trend. All this board does allows me to then decide for myself what to do.
I have to say, I was surprised by an earlier post, as I think this board is at its best.
scottrade uses trade ideas on the elite download scanner
dam right, lol
agree,
Form 8-K for INTERNET PATENTS CORP
10-Jan-2012
Change in Directors or Principal Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements with Certain Officers.
On January 4, 2012, the Compensation Committee of the Board of Directors (the "Committee") of Internet Patents Corporation (formerly InsWeb Corporation) approved the 2012 compensation plan for the Company's executive officers. In approving the 2012 compensation plan, the Committee considered, among other factors, the Company's financial and operating performance, changes to the Company's business model, market conditions, and general compensation trends for publicly traded companies. The objectives of the compensation plan are to attract, motivate and retain talented and dedicated employees, and to provide incentives to further the Company's interests and those of our stockholders.
As recommended by the Committee and approved by the Board of Directors, the 2012 annual cash compensation for Hussein Enan (CEO and Interim CFO) and Eric Loewe (General Counsel and Secretary) are unchanged from 2011. The 2012 annual base cash compensation for Steve Yasuda (Chief Accounting Officer) increases from $169,753 to $254,629.50 and is retroactive to December 1, 2011.
2012 Base Salary Stock Options
Hussein A. Enan (CEO and Interim CFO) $ 300,000.00 -
Steven J. Yasuda (CAO) $ 254,629.50 -
L. Eric Loewe (General Counsel) $ 218,360.00 -
The Compensation Committee also approved the immediate payment of a special, lump-sum cash bonus to each of Mr. Enan, Mr. Yasuda and Mr. Loewe in recognition of their services in completing the sale of assets to Bankrate, Inc.
Cash Bonus
Hussein A. Enan (CEO and Interim CFO) $ 100,000.00
Steven J. Yasuda (CAO) $ 10,000.00
L. Eric Loewe (General Counsel) $ 50,000.00
fat cats get it both ways with stock up ah
Internet Patents (INSW) Declares $5.00/Share Special Dividend; 62.6% Yield
* Internet Patents (INSW) shares resume trading up 18%
* Shares of Internet Patents (INSW) to resume trading at 5pm ET
* Internet Patents (INSW) Declares $5.00/Share Special Dividend; 62.6% Yield
* Internet Patents (INSW) (formerly Insweb) declares special cash dividend of $5/share
* Internet Patents Corporation, Formerly InsWeb Corporation, Announces Special Cash Distribution
More News related to INSW
More News related to Dividends
* Morgan Stanley Income Securities, Inc. (ICB) Lowers Monthly Dividend 3.4% to $0.07; 4.8% Yield
* Internet Patents (INSW) Declares $5.00/Share Special Dividend; 62.6% Yield
* Procter & Gamble Co. (PG) Declares $0.525 Quarterly Dividend; 3.2% Yield
* Gladstone Capital Corp (GLAD) Declares $0.07 Feb. Dividend; 10.1% Yield
* Gladstone Capital Corp (GLAD) Declares $0.07 Jan. Dividend; 10.1% Yield
More News related to Dividends
January 10, 2012 4:36 PM EST
Internet Patents (NASDAQ: INSW) declared a special dividend of $5.00 per share.
The dividend will be payable on March 9, 2012, to stockholders of record on February 10, 2012, with an ex-dividend date of March 12, 2012.
The annual yield on the dividend is 62.6 percent.
in and out today, but cleaned up on hma and thrx, great day, thanks Yak! u be smokin'
William O'Neil of IBD says that the most successful traders are in the market 7.5 months of the year.
A+ pickup Dolo. Last good play of 2011, Happy New Year All!
I'm so sorry, stoploss. My prayers are with you and your family.
GIL trending up today $18.95
I got out at 38.06 ah, thanks Yak:)
KV/A & KV/B LAWSUIT
NOTICE TO PURCHASERS OF K-V PHARMACEUTICAL COMPANY
SECURITIES BETWEEN FEBRUARY 14,2011 AND APRIL 4, 2011
[see below, respond before December 12, 2011]
Notice is hereby given that a class action lawsuit was filed by Kessler Topaz Meltzer & Check, LLP in the United
States District Court for the Eastern District of Missouri on behalf of purchasers of the securities of K- V Pharmaceutical
Company (NYSE: KV-A or KV-B) ("K-V" or the "Company"), who purchased or otherwise acquired K-V Pharmaceutical
securities between February 14,2011 and April 4, 2011, inclusive (the "Class Period"). If you are a member of this class,
you can view a copy of the Complaint or join this class action online at http://www.ktmc.com/cases/k-vpharmaceutical/.
The Complaint charges K- V and certain of its officers with violations of the Securities Exchange Act of 1934. K- V
is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. The Complaint
alleges that the defendants failed to disclose and misrepresented the following material adverse facts which were known to
them or recklessly disregarded by them: (1) that the FDA had not in fact granted K-V exclusive distribution rights over
hydroxyprogesterone caproate; (2) that the Company had not expanded access of Makena in any meaningful way to low-
income and at-risk groups; (3) that the exorbitant $1,500 per injection price of Makena would reduce the availability of the
drug to physicians and patients and decrease meaningful demand; (4) that the Company lacked adequate internal and
financial controls; and (5) that, as a result of the foregoing, the Company's statements about Makena's price, distribution
program and the likelihood of financial success for the Company were lacking in any reasonable basis when made. On
March 17, 2011, two U.S. Senators announced that they had sent a letter to the Federal Trade Commission ("FTC") requesting a formal investigation into potential anticompetitive conduct arising out of K-V's decision to drastically increase the price of Makena after receiving exclusive distribution rights. On March 30, 2011, the FDA announced that, contrary to defendants' assertions, the agency did not intend to take enforcement action against pharmacies that compound 17P. On April 1,2011, the defendants announced that they were reducing the price of Makena by nearly 55%, to $690 per injection.
On April 4, 2011, an article published in Bloomberg revealed that even with the price reduction, many physicians
would still not recommend Makena to their patients, believing the cost of the drug to be too high. One physician spoke of the hostility generated by K- V's initial pricing of the drug, as well as the fact there was no guarantee that a patient or an insurance company would pay for Makena (meaning that a physician would have to assume financial responsibility for inventory if they bought the drug from K-V). Upon these revelations, shares of the Company's series A stock fell $0.39 per share, or over 7 percent, to close on April 4, 2011 at $5.00 per share, on heavy trading volume. Similarly, shares of the Company's series B stock declined approximately $0.34 per share, or over 6 percent, to close on April 4, 2011 at $5.03 per share. During the Class Period, K-V shares had traded as high as over $13.00 per share.
If you are a member of the class described above, you may, no later than December 19, 2011, move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of their choice, or may choose to do nothing and remain an inactive class member.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect
to these matters, please contact Kessler Topaz Meltzer & Check, LLP (David M. Promisloff, Esq.) toll free at 1-888-299-
7706 or 1-610-667-7706, or via e-mail at info@ktmc.com before December 12, 2011. For more information about Kessler Topaz Meltzer & Check, LLP, please visit our website at www.ktmc.com. If you would like additional information
about the suit, please fill out the attached form as promptly as possible and return it by fax to 610-667-7056, or by mail in
the enclosed envelope.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
David M. Promisloff, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-888-299-7706 (toll free) or 1-610-667-7706
Or by e-mail at info@ktmc.com
really nice trade, Yak.
emphasis on 'moron'
Serf, you made a good point. The marketplace is intended to broker investments in corporations and they use the money to become better companies. Both parties benefit. It worked well for decades. It would be neat to be able to bypass wall street and deal with corporations directly, terms and all.
spx close 10/31 1254
GS hod
just remember if Jaimie Dimon or Cramer call you at 4 in the morning for stock advise, make sure you get an invite to the Hamptons, lol.
Great interview, Yak:))
thanks, will do. Have a great weekend good man!
apkt simply amazing [not the orange juice],thanks Yak! out + 1.40, sold on way up=check. Glad you're here today.
it's working for me too now, good post.
I brought a lot of old 'reactions' to Yakgroup, I'm replacing with the new tools and training, eventually automatic. "The more one can balance their fear and greed, the more trading starts to make sense." ie. less fear, more greed when a stock is at an historic bottom and makes sense... and less greed, more fear when stock's hit it's target. Head for the hills and sell.
Rest In Peace Steve Jobs.
goldline bought their website, j/k
congrats Feddy, finishes off a great day!
another beauty, Yak, out 41.28 ty